SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Covalon Technologies Ltd. CVALF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Covalon Technologies Ltd. (CVALF) is a Biotechnology company in the Healthcare sector, currently trading at $1.45. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $33M, +23%/yr average growth. Net income is $2M, growing at +63.6%/yr. Net profit margin is 6.3% (thin). Gross margin is 53.2% (+11.9 pp trend).

Balance sheet: total debt is $2M against $31M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 8.36 (strong liquidity). Debt-to-assets is 6.2%. Total assets: $36M.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 50/100 (Partial), Future ?/100 (Fail), Income 45/100 (Partial).

CVALF SharesGrow Score Overview

70/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 50/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CVALF

CVALF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CVALF: +23%/yr revenue is, +63.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CVALF: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CVALF: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 8.36 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CVALF: Gross margin is 53.2% (+11.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

CVALF: Net profit margin is 6.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.16-2.14

Volume600

Avg Volume (30D)7.03K

Market Cap$40.05M

Beta (1Y)-0.01

Dividend Yield$0.1063

Share Statistics

EPS (TTM)0.08

Shares Outstanding$27.41M

IPO Date2007-04-18

CEOBrent Ashton

Financial Highlights & Ratios

Revenue (TTM)$32.82M

Gross Profit$17.47M

EBITDA$2.72M

Net Income$2.06M

Operating Income$1.76M

Total Cash$17.37M

Total Debt$2.25M

Net Debt$-15.11M

Total Assets$36.12M

Price / Earnings (P/E)19.3

Price / Sales (P/S)1.22

Analyst Forecast

Company Info

CountryCA

ExchangeOther OTC

CurrencyUSD

ISINCA22282D3022

Price Chart

CVALF

Covalon Technologies Ltd. ↗ · Other OTC

Healthcare • Biotechnology

1.16 52WK RANGE 2.14

People Also View

Small Pharma Inc.

Biotron Limited

Resverlogix Corp.

Mosaic ImmunoEngineering Inc.

Advanced Proteome Therapeutics Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message